Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. biocopy

BIOCOPY SIGNED

BIOCOPY: the new biomolecule copying and screening solution for diagnostics and therapeutics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BIOCOPY project word cloud

Explore the words cloud of the BIOCOPY project. It provides you a very rough idea of what is the project "BIOCOPY" about.

biotechnology    feasibility    discovery    responsible    pharmaceuticals    template    free    biology    11    spin    business    approval    completely    opens    photocopier    vaccine    company    engineering    acute    analogous    biocopy    dimensions    enzymes    days    character    upfront    2025    coatings    innovative    biomolecules    rna    vaccines    biotech    awarded    dna    tailor    physics    biochemical    billion    label    either    candidates    diagnostics    academic    expertise    surface    plan    made    pharma    revenues    recovered    services    molecular    mixes    100    payments    annum    off    assay    line    biosensors    technique    market    patented    transfer    molecules    disruptive    antibodies    protein    technological    generation    manufacturing    borned    5m    team    freiburg    supplying    copy    royalty    coated    companies    microsystems    bioactive    covers    university    dollar    copied    60    clinical    catalysts    obtaining    world    2019    milestone    projected    first    therapeutics    commercialization    describing    cheaper    binding    output    screenings    drug   

Project "BIOCOPY" data sheet

The following table provides information about the project.

Coordinator		 BIOCOPY GMBH 

Organization address
address: SPECHTWEG 25
city: FREIBURG IM BREISGAU
postcode: 79110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.biocopy.de/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOCOPY GMBH DE (FREIBURG IM BREISGAU) coordinator 50˙000.00

Map

 Project objective

'BioCopy is a spin-off company borned in the University of Freiburg. We have developed an innovative, patented technique to copy biomolecules analogous to a photocopier. A DNA-coated surface is used as copy template. By supplying different biochemical 'copy mixes', either a DNA, a RNA or a protein copy is generated. After the copy process, the copied biomolecules can be analyzed label-free for their specific binding to target molecules and recovered as potential candidates for a future use as therapeutics or diagnostics. The BioCopy technology completely opens up new dimensions for drug development, vaccines, antibodies, enzymes, catalysts, bioactive coatings, and biosensors and it has are more than 40 future applications. We plan to offer 3 products and services to pharma and biotech companies, related with high- output and cheaper molecular biology screenings. The most promising line is the tailor-made discovery of vaccine candidates within two days. This will have a disruptive character, because the first generation of a vaccine is a billion-dollar market, projected to rise $60 billion on 2019, with 11% growth per annum, and to $100 billion by 2025. BioCopy will provide vaccine candidates to pharmaceuticals, obtaining revenues through upfront, milestone and royalty payments, and they will be responsible for the vaccine´s clinical development, approval and distribution. The multi-awarded BioCopy team covers business know-how and expertise in biology, physics, manufacturing systems engineering, assay development and microsystems technology. BioCopy aims to contribute to the European challenges related with advanced biotechnology applications in pharma sector, and to increase the technological transfer from the academic world into the manufacturing sector. During phase 1 we will build up a detailed business plan and a feasibility study, describing all the needed activities in order to reach BioCopy commercialization. We will need about €2.5M in phase 2.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOCOPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOCOPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

Primavera (2018)

Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More